Advancing Light Therapy Research to Enhance Quality of Life for Parkinson's Patients This trial is important becau ...

AbbVie Inc. announced positive data from a third late-stage trial ... said a third Phase 3 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson’s disease met its primary ...

A Phase 3 trial is ... is occurring in Parkinson's disease,” says Mark Frasier, chief scientific officer of the MJFF. “The Foundation is urgently driving the next stages of development of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...

Parkinson's disease is an illness that affects the part of your brain that controls how you move your body. Some people with Parkinson’s first notice weakness, difficulty walking, and stiff muscles.